<!DOCTYPE html>
<html>
  
  <!-- Begin Jekyll SEO tag v2.8.0 -->
<title>Myeloablative therapy and cis-retinoic acid confer better survival to high-risk neuroblastoma patients | Ciência médica</title>
<meta name="generator" content="Jekyll v3.10.0" />
<meta property="og:title" content="Myeloablative therapy and cis-retinoic acid confer better survival to high-risk neuroblastoma patients" />
<meta name="author" content="Francisco H C Felix" />
<meta property="og:locale" content="en_us" />
<meta name="description" content="The results of study CCG-3891 were published in March 2009 on Journal of Clinical Oncology. The multicentric study has shown that high-dose myeloablative chemotherapy followed by stem-cell rescue is better than conventional chemotherapy for high-risk neuroblastoma patients. Moreover, addition of cis-retinoic acid treatment after chemotherapy could boost survival in both groups. Standard therapy for high-risk neuroblastoma patients should be therefore myeloablative chemotherapy with autologous stem cell rescue followed by cis-retinoic acid treatment." />
<meta property="og:description" content="The results of study CCG-3891 were published in March 2009 on Journal of Clinical Oncology. The multicentric study has shown that high-dose myeloablative chemotherapy followed by stem-cell rescue is better than conventional chemotherapy for high-risk neuroblastoma patients. Moreover, addition of cis-retinoic acid treatment after chemotherapy could boost survival in both groups. Standard therapy for high-risk neuroblastoma patients should be therefore myeloablative chemotherapy with autologous stem cell rescue followed by cis-retinoic acid treatment." />
<link rel="canonical" href="https://fhcflx.github.io/ciencia-medica/2009/03/18/myeloablative-therapy-and-cis-retinoic.html" />
<meta property="og:url" content="https://fhcflx.github.io/ciencia-medica/2009/03/18/myeloablative-therapy-and-cis-retinoic.html" />
<meta property="og:site_name" content="Ciência médica" />
<meta property="og:type" content="article" />
<meta property="article:published_time" content="2009-03-18T22:42:00-03:00" />
<meta name="twitter:card" content="summary" />
<meta property="twitter:title" content="Myeloablative therapy and cis-retinoic acid confer better survival to high-risk neuroblastoma patients" />
<script type="application/ld+json">
{"@context":"https://schema.org","@type":"BlogPosting","author":{"@type":"Person","name":"Francisco H C Felix"},"dateModified":"2009-03-18T22:42:00-03:00","datePublished":"2009-03-18T22:42:00-03:00","description":"The results of study CCG-3891 were published in March 2009 on Journal of Clinical Oncology. The multicentric study has shown that high-dose myeloablative chemotherapy followed by stem-cell rescue is better than conventional chemotherapy for high-risk neuroblastoma patients. Moreover, addition of cis-retinoic acid treatment after chemotherapy could boost survival in both groups. Standard therapy for high-risk neuroblastoma patients should be therefore myeloablative chemotherapy with autologous stem cell rescue followed by cis-retinoic acid treatment.","headline":"Myeloablative therapy and cis-retinoic acid confer better survival to high-risk neuroblastoma patients","mainEntityOfPage":{"@type":"WebPage","@id":"https://fhcflx.github.io/ciencia-medica/2009/03/18/myeloablative-therapy-and-cis-retinoic.html"},"url":"https://fhcflx.github.io/ciencia-medica/2009/03/18/myeloablative-therapy-and-cis-retinoic.html"}</script>
<!-- End Jekyll SEO tag -->

  <head>
  <meta charset="utf-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="viewport" content="width=device-width, initial-scale=1">

  <!-- Begin Jekyll SEO tag v2.8.0 -->
<title>Myeloablative therapy and cis-retinoic acid confer better survival to high-risk neuroblastoma patients | Ciência médica</title>
<meta name="generator" content="Jekyll v3.10.0" />
<meta property="og:title" content="Myeloablative therapy and cis-retinoic acid confer better survival to high-risk neuroblastoma patients" />
<meta name="author" content="Francisco H C Felix" />
<meta property="og:locale" content="en_us" />
<meta name="description" content="The results of study CCG-3891 were published in March 2009 on Journal of Clinical Oncology. The multicentric study has shown that high-dose myeloablative chemotherapy followed by stem-cell rescue is better than conventional chemotherapy for high-risk neuroblastoma patients. Moreover, addition of cis-retinoic acid treatment after chemotherapy could boost survival in both groups. Standard therapy for high-risk neuroblastoma patients should be therefore myeloablative chemotherapy with autologous stem cell rescue followed by cis-retinoic acid treatment." />
<meta property="og:description" content="The results of study CCG-3891 were published in March 2009 on Journal of Clinical Oncology. The multicentric study has shown that high-dose myeloablative chemotherapy followed by stem-cell rescue is better than conventional chemotherapy for high-risk neuroblastoma patients. Moreover, addition of cis-retinoic acid treatment after chemotherapy could boost survival in both groups. Standard therapy for high-risk neuroblastoma patients should be therefore myeloablative chemotherapy with autologous stem cell rescue followed by cis-retinoic acid treatment." />
<link rel="canonical" href="https://fhcflx.github.io/ciencia-medica/2009/03/18/myeloablative-therapy-and-cis-retinoic.html" />
<meta property="og:url" content="https://fhcflx.github.io/ciencia-medica/2009/03/18/myeloablative-therapy-and-cis-retinoic.html" />
<meta property="og:site_name" content="Ciência médica" />
<meta property="og:type" content="article" />
<meta property="article:published_time" content="2009-03-18T22:42:00-03:00" />
<meta name="twitter:card" content="summary" />
<meta property="twitter:title" content="Myeloablative therapy and cis-retinoic acid confer better survival to high-risk neuroblastoma patients" />
<script type="application/ld+json">
{"@context":"https://schema.org","@type":"BlogPosting","author":{"@type":"Person","name":"Francisco H C Felix"},"dateModified":"2009-03-18T22:42:00-03:00","datePublished":"2009-03-18T22:42:00-03:00","description":"The results of study CCG-3891 were published in March 2009 on Journal of Clinical Oncology. The multicentric study has shown that high-dose myeloablative chemotherapy followed by stem-cell rescue is better than conventional chemotherapy for high-risk neuroblastoma patients. Moreover, addition of cis-retinoic acid treatment after chemotherapy could boost survival in both groups. Standard therapy for high-risk neuroblastoma patients should be therefore myeloablative chemotherapy with autologous stem cell rescue followed by cis-retinoic acid treatment.","headline":"Myeloablative therapy and cis-retinoic acid confer better survival to high-risk neuroblastoma patients","mainEntityOfPage":{"@type":"WebPage","@id":"https://fhcflx.github.io/ciencia-medica/2009/03/18/myeloablative-therapy-and-cis-retinoic.html"},"url":"https://fhcflx.github.io/ciencia-medica/2009/03/18/myeloablative-therapy-and-cis-retinoic.html"}</script>
<!-- End Jekyll SEO tag -->


  <!--
 <link rel="alternate" hreflang="en-us" href="/ciencia-medica/2009/03/18/myeloablative-therapy-and-cis-retinoic.html" />
  -->
 <!-- <link rel="alternate" type="application/rss+xml" title="" href="/ciencia-medica"> -->

  <title>Myeloablative therapy and cis-retinoic acid confer better survival to high-risk neuroblastoma patients</title>
  <meta name="description" content="The results of study CCG-3891 were published in March 2009 on Journal of Clinical Oncology. The multicentric study has shown that high-dose myeloablative che...">

  <!-- Google Fonts loaded here depending on setting in _data/options.yml true loads font, blank does not-->
  
    <link href='https://fonts.googleapis.com/css?family=Lato:400,400italic' rel='stylesheet' type='text/css'>
  

  <!-- Load up MathJax script if needed ... specify in /_data/options.yml file-->
  
    <script type="text/javascript" id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
  

  <link rel="stylesheet" type="text/css" href="/ciencia-medica/css/tufte.css">
  <!-- <link rel="stylesheet" type="text/css" href="/ciencia-medica/css/print.css" media="print"> -->

  <link rel="canonical" href="https://fhcflx.github.io/ciencia-medica/2009/03/18/myeloablative-therapy-and-cis-retinoic.html">
  <link rel="icon"
        type="image/png"
        href="/assets/img/badge.png">

  <!-- <link rel="alternate" type="application/rss+xml" title="Ciência médica" href="https://fhcflx.github.io/ciencia-medica" /> -->

  <link rel="apple-touch-icon" sizes="180x180" href="/ciencia-medica/apple-touch-icon.png">
  <link rel="icon" type="image/png" sizes="32x32" href="/ciencia-medica/favicon-32x32.png">
  <link rel="icon" type="image/png" sizes="16x16" href="/ciencia-medica/favicon-16x16.png">
  <link rel="manifest" href="/ciencia-medica/site.webmanifest">
  <link rel="mask-icon" href="/ciencia-medica/safari-pinned-tab.svg" color="#5bbad5">
  <link rel="shortcut icon" href="/ciencia-medica/favicon.ico">
  <meta name="msapplication-TileColor" content="#da532c">
  <meta name="msapplication-config" content="/ciencia-medica/browserconfig.xml">
  <meta name="theme-color" content="#ffffff">

</head>

  <body>
    <!--- Hader and nav template site-wide -->
<header>
    <a class="site-title" href="/ciencia-medica/index.html"></a>
    <nav class="group">
	<a href="/ciencia-medica/"><img class="badge" src="/ciencia-medica/assets/img/mybadge.png" alt="CH"></a>
        
	
		
		    
		      <a href="/ciencia-medica/index-en.html">Medical Science</a>
		    
	    
  	
		
		    
		      <a href="/ciencia-medica/all-posts/index.html">All</a>
		    
	    
  	
		
		    
		      <a href="/ciencia-medica/cancer2/index.html">Cancer</a>
		    
	    
  	
		
		    
		      <a href="/ciencia-medica/nobel/index.html">Nobel Prize</a>
		    
	    
  	
		
		    
		      <a href="/ciencia-medica/about/index.html">About</a>
		    
	    
  	
		
		    
		      <a href="/ciencia-medica/markers/index.html">Tags</a>
		    
	    
  	

  </nav>
<div class="wrapper" style="text-align: right; line-height: 2em">
  
  
    
      <a href="/ciencia-medica/2009/03/18/myeloablative-therapy-and-cis-retinoic.html" class="en">English</a>
    
  
  
  
</div>
</header>

    <article class="group">
      <h1>Myeloablative therapy and cis-retinoic acid confer better survival to high-risk neuroblastoma patients</h1>
<p class="subtitle">

18
Março
  
2009</p>





<ul class="tags">
  
    <li><a href="/ciencia-medica/marcadores#Cancer" class="tag">Cancer</a></li>
  
    <li><a href="/ciencia-medica/marcadores#Neuroblastoma" class="tag">Neuroblastoma</a></li>
  
    <li><a href="/ciencia-medica/marcadores#Clinical pharmacology" class="tag">Clinical pharmacology</a></li>
  
    <li><a href="/ciencia-medica/marcadores#Imunotherapy" class="tag">Imunotherapy</a></li>
  
</ul>

<p>The results of study CCG-3891 were published in March 2009 on Journal of Clinical Oncology. The multicentric study has shown that high-dose myeloablative chemotherapy followed by stem-cell rescue is better than conventional chemotherapy for high-risk neuroblastoma patients. Moreover, addition of cis-retinoic acid treatment after chemotherapy could boost survival in both groups. Standard therapy for high-risk neuroblastoma patients should be therefore myeloablative chemotherapy with autologous stem cell rescue followed by cis-retinoic acid treatment.
<!--more--></p>

<p>Read the article <a href="https://jco.ascopubs.org/content/27/7/1007.full.pdf+html">here</a>.</p>

<p>Postagem original no Pharmakon <a href="https://pharmak.blogspot.com/2009/03/myeloablative-therapy-and-cis-retinoic.html">aqui</a>.</p>


<article style="max-width: 90%;">
  <div id="disqus_thread"></div>
  <script>
    /**
     *  RECOMMENDED CONFIGURATION VARIABLES: EDIT AND UNCOMMENT THE SECTION BELOW TO INSERT DYNAMIC VALUES FROM YOUR PLATFORM OR CMS.
     *  LEARN WHY DEFINING THESE VARIABLES IS IMPORTANT: https://disqus.com/admin/universalcode/#configuration-variables
     */
    /*
    var disqus_config = function () {
        this.page.url = PAGE_URL;  // Replace PAGE_URL with your page's canonical URL variable
        this.page.identifier = PAGE_IDENTIFIER; // Replace PAGE_IDENTIFIER with your page's unique identifier variable
    };
    */
      (function() {  // DON'T EDIT BELOW THIS LINE
          var d = document, s = d.createElement('script');
              s.src = 'https://pharmak-on.disqus.com/embed.js';

            s.setAttribute('data-timestamp', +new Date());
            (d.head || d.body).appendChild(s);
        })();
  </script>
  <noscript>Please enable JavaScript to view the <a href="https://disqus.com/?ref_noscript" rel="nofollow">comments powered by Disqus.</a></noscript>
</article>


    </article>
    <span class="print-footer">Myeloablative therapy and cis-retinoic acid confer better survival to high-risk neuroblastoma patients - March 18, 2009 - fhcflx</span>
    <footer>
  <hr class="slender">
  <ul class="footer-links">
    
      <li>
        <a href="https://www.twitter.com/neurodiversie" target="_blank" rel="noopener">
          <span class="icon-twitter"></span>
        </a>
      </li>
    
      <li>
        <a href="https://github.com/fhcflx/ciencia-medica" target="_blank" rel="noopener">
          <span class="icon-github"></span>
        </a>
      </li>
    
      <li>
        <a href="https://www.instagram.com/neuro.oncology" target="_blank" rel="noopener">
          <span class="icon-instagram"></span>
        </a>
      </li>
    
      <li>
        <a href="https://www.threads.net/neuro.oncology" target="_blank" rel="noopener">
          <span class="icon-threads"></span>
        </a>
      </li>
    
      <li>
        <a href="https://bsky.app/profile/neurodiversie.bsky.social" target="_blank" rel="noopener">
          <span class="icon-bluesky"></span>
        </a>
      </li>
    
      <li>
        <a href="https://www.linkedin.com/in/franciscofelix" target="_blank" rel="noopener">
          <span class="icon-linkedin"></span>
        </a>
      </li>
    
    <!-- <li><a href=https://travis-ci.org/fhcflx/ciencia-medica ><img alt='travis-ci build' src=https://img.shields.io/travis/fhcflx/ciencia-medica.svg?colorA=a00000&colorB=a00000></a></li> -->
  </ul>
<div class="credits">
<span>&copy; 2025 &nbsp;&nbsp;FHCFLX</span></br> <br>

<span>This site was created with the <a href="https://github.com/clayh53/tufte-jekyll">Tufte theme for Medical Science </a> on <a href="https://jekyllrb.com">Jekyll</a>.</span>

</div>
</footer>

    
<script src="https://cdn.jsdelivr.net/npm/cookieconsent@3/build/cookieconsent.min.js"></script>
<link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/cookieconsent@3/build/cookieconsent.min.css" />
<style>
.cc-window.cc-banner {
  background: #fffff8 !important; /* cor de fundo do blog */
  color: #a00000 !important;      /* cor de texto do blog */
  border-radius: 8px !important;
  box-shadow: 0 2px 16px rgba(0,0,0,0.10);
  border: 1px solid #a00000 !important;
  font-family: et-bembo, Palatino, "Palatino Linotype", "Palatino LT STD", "Book Antiqua", Georgia, serif !important;
  font-size: 1.1rem !important;
}
.cc-btn {
  background: #a00000 !important; /* cor principal do blog */
  color: #fff !important;
  border-radius: 4px !important;
  font-family: inherit !important;
  font-size: 1rem !important;
  box-shadow: none !important;
  border: none !important;
  padding: 0.5em 1.2em !important;
  transition: background 0.2s;
}
.cc-btn:hover {
  background: #14a7d0 !important; /* cor de destaque já usada */
  color: #fff !important;
}
.cc-link {
  color: #14a7d0 !important;
  text-decoration: underline;
  font-weight: bold;
}
</style>
<script>
window.addEventListener("load", function(){
  window.cookieconsent.initialise({
    palette: {
      popup: { background: "#fffff8", text: "#a00000" },
      button: { background: "#a00000", text: "#fff" }
    },
    theme: "classic",
    content: {
      message: `This site uses cookies to enhance your experience.`,
      dismiss: `Got it!`,
      link: `Learn more`,
      href: `/about/privacy-policy`
    }
  })
});
</script>

  </body>
</html>
